资讯内容 Content

[AACE2012]2型糖转化医学研究进展
——宁光教授专访
国际糖尿病网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

作者:宁光 2012/5/25 16:04:00    加入收藏
内容概要:Dr Ning: Pioglitazone and rosiglitazone are similar kinds of drug as TZDs but there is a huge difference in their mechanisms of action. Firstly, pioglitazone lowers the lipids in type 2 diabetes and rosiglitazone doesn’t have this effect. Secondly rosiglitazone causes edema which increases risk for heart failure,

  宁光   上海交通大学医学院附属瑞金医院

  <International Diabetes>: What do you think is the main mechanism of pioglitazone to reduce cardiovascular risk?
  Dr Ning: Pioglitazone and rosiglitazone are similar kinds of drug as TZDs but there is a huge difference in their mechanisms of action. Firstly, pioglitazone lowers the lipids in type 2 diabetes and rosiglitazone doesn’t have this effect. Secondly rosiglitazone causes edema which increases risk for heart failure, however pioglitazone does not have this effect and there is less heart failure associated with it.  

  《国际糖尿病》:您认为吡格列酮降低心血管风险的主要机制有哪些?
  宁光教授:吡格列酮和罗格列酮虽然同属TZD类药物,但两者的作用机制存在很大的差别。首先,吡格列酮能够降低2型糖尿病患者的血脂,而罗格列酮则无上述效应。其次,罗格列酮能够引发水肿增加心力衰竭的发生风险,但吡格列酮无上述作用因而与其相关的心衰发生风险较低。正因而如此,罗格列酮能够增加某些心血管事件的发生风险,但到目前为止,吡格列酮并无这种副作用。
 

  <International Diabetes>:Translational medicine is a hot topic attracting a lot of attention these days. You published an article in 2011 reporting that your team found genes which are associated with type 2 diabetes in Han Chinese. Can you tell us about the progress of that study?
  Dr Ning: Translational medicine is very important so we should translate laboratory and academic study into clinical practice. We performed a study to look at the association between gene variation and the development of type 2 diabetes. We found two genes in Han Chinese that may be associated with type 2 diabetes. This is still the early stages of the study. Up until now, we cannot apply our result to clinical practice as gene determination is not possible in the clinical setting yet. In the future we can apply gene variation to the diagnosis of diabetes. More useful maybe is the role of this gene variation in determining responses to drugs. People carrying these genes may not respond to some anti-diabetes agents. On the other hand, people who carry the genes may have a better response to certain diabetes agents. Maybe we can do that and maybe we can’t.

  《国际糖尿病》:转化医学称为近年来研究关注的热点。您在2011年发表的文章报道发现了与汉族人2型糖尿病相关的基因。您能够介绍一下该研究的最新进展?
  宁光教授:转化医学具有重要的意义,因此我们需要将实验室及学术研究的结果转化并应用至临床实践中。我们进行了一项研究来观察基因变异与2型糖尿病发病的相关性。结果在汉族人中发现了2个与2型糖尿病相关的基因。目前该研究尚处在早期阶段。到目前为止,因为临床上尚无法测定出基因差异,所以我们还无法将其结果应用至临床实践中。但我相信,未来我们将能够采用基因变异来诊断糖尿病。同时基因变异可能会在机体对药物的反应中发挥更重要的作用。携带这些基因的人们可能对某些降糖药物没有反应,另一方面携带这些基因者可能对某些特定降糖药的反应更佳。
 



[1]  [2]  下一页

 延伸阅读
注册

网友评论仅供其表达个人看法,并不表明国际糖尿病同意其观点或证实其描述。 发表评论需登陆

 
关于本站 | 设为首页 | 加入收藏 | 站长邮箱 | 友情链接 | 版权申明

国际糖尿病(www.idiabetes.com.cn)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。

国际糖尿病 版权所有  2008-2018 idiabetes.com.cn  All Rights Reserved